Conditions: Ovarian Cancer Peritoneal Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 51
Healthy volunteers: no

Brief summary:
The primary purpose of this trial is to estimate the drug effect on tumors in patients with ovarian or primary peritoneal cancers. Patients will receive Pemetrexed every 21 days until disease progression or unacceptable toxicity. This medication will be given over 10 minutes and may be administered intravenously (IV), through a vein in your arm. Vitamin supplementation is a required part of this study.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: pemetrexed
Intervention descriptions: intervention 1: 900 mg/m2, intravenous (IV), every 21 days, until disease progression

Protocol document: